Bessemer Group’s Xeris Biopharma Holdings XERS Stock Holding History

Bessemer Group’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6	Closed	–	–	2657
2026 Q1	$0	Sell	6 -62	-91%	-$411	﹤0.01%	2703
2025 Q4	$1K	Hold	68	–	–	﹤0.01%	2504
2025 Q3	$1K	Buy	+68	New	+$452	﹤0.01%	2455

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bessemer Group's XERS Position: Q2 2026 in Review

Bessemer Group sold out of Xeris Biopharma Holdings (XERS) in Q2 2026, closing a stake of 6 shares.

Bessemer Group first reported a position in XERS in Q3 2025 and held it in 3 quarters. The position peaked at $1K in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Bessemer Group reported no remaining Xeris Biopharma Holdings position as of Q2 2026 after selling out during the quarter.
Bessemer Group sold 6 Xeris Biopharma Holdings shares in Q2 2026.
Bessemer Group first reported a position in Xeris Biopharma Holdings in Q3 2025 and held it in 3 quarters.
Bessemer Group's Xeris Biopharma Holdings position peaked at $1K in Q4 2025.
241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.